8-K: Myriad Genetics Reports Strong Q3 Growth, Updates Full-Year Guidance Amidst Payor Coverage Challenges

Myriad Genetics announced an 11% year-over-year revenue increase for the third quarter of 2024, driven by growth in pharmacogenomics and prenatal testing, while also updating its full-year financial guidance.

Summary

• Myriad Genetics reported an 11% increase in revenue for the third quarter of 2024, reaching $213 million, compared to $191.9 million in the same period last year.
• The company's pharmacogenomics and prenatal testing segments were key drivers of this growth, with increases of 34% and 10% respectively.
• Myriad's GAAP net loss improved significantly to $22.1 million, compared to a loss of $61.3 million in the third quarter of 2023.
• Adjusted EBITDA for the quarter increased to $14.1 million, up from $1.4 million in the prior year.
• The company updated its full-year 2024 revenue guidance to a range of $837 million to $843 million and adjusted earnings per share to a range of $0.12 to $0.14.
• UnitedHealthcare will discontinue coverage for certain multi-gene panel pharmacogenetic tests, including GeneSight, effective January 1, 2025, which could impact Myriad's revenue.
• Myriad generated approximately $10 million in GeneSight revenue from UnitedHealthcare's commercial population in the third quarter of 2024 and $40 million over the trailing twelve months.
• Test volumes increased by 6% year-over-year to 376,000 in the third quarter of 2024.
• The company's gross margin was 70.2% in the third quarter of 2024, a slight increase of 20 basis points year-over-year.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong revenue growth and improved profitability, but the negative impact of UnitedHealthcare's coverage decision and the ongoing net loss temper the overall outlook.

Positives

• Myriad Genetics achieved an 11% year-over-year revenue growth in the third quarter of 2024.
• The company's pharmacogenomics and prenatal segments showed strong growth, with 34% and 10% increases respectively.
• The net loss improved significantly, decreasing from $61.3 million to $22.1 million year-over-year.
• Adjusted EBITDA saw a substantial increase, rising from $1.4 million to $14.1 million year-over-year.
• Myriad updated its full-year revenue guidance to a range of $837 million to $843 million.
• Adjusted EPS guidance was updated to a range of $0.12 to $0.14.
• Test volumes increased by 6% year-over-year.
• The company's gross margin improved slightly to 70.2%.

Negatives

• UnitedHealthcare will discontinue coverage for certain multi-gene panel pharmacogenetic tests, including GeneSight, effective January 1, 2025.
• Myriad generated approximately $10 million in GeneSight revenue from UnitedHealthcare's commercial population in the third quarter, which is now at risk.
• The company still reported a net loss of $22.1 million for the quarter, although it is a significant improvement from the previous year.
• Tumor profiling revenue decreased by 8% for the nine months ended September 30, 2024.

Risks

• The discontinuation of coverage for GeneSight by UnitedHealthcare poses a significant risk to future revenue.
• The company faces risks related to changes in governmental or private insurers coverage and reimbursement levels for its tests.
• There are risks related to increased competition and the development of new competing tests.
• Myriad faces the risk of not being able to develop or achieve commercial success for additional tests in a timely manner.
• The company may not be able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms.
• There are risks related to security breaches, loss of data and other disruptions, including from cyberattacks.

Future Outlook

Myriad Genetics updated its full-year 2024 revenue guidance to a range of $837 million to $843 million and adjusted earnings per share to a range of $0.12 to $0.14. The company is focused on commercializing new products and addressing payor coverage challenges, particularly with UnitedHealthcare.

Management Comments

• Paul J. Diaz, President and CEO of Myriad Genetics, stated that the company has delivered 13% revenue growth year-to-date and is focused on delivering profitable growth and free cash flow.
• Management expressed disappointment with UnitedHealthcare's decision to restrict access to GeneSight and is actively engaging with them to find a positive resolution for patients.

Industry Context

The announcement comes amid increasing scrutiny of genetic testing coverage by insurance providers. The decision by UnitedHealthcare to discontinue coverage for multi-gene panel pharmacogenetic tests reflects a broader trend of payors seeking more evidence of clinical utility and cost-effectiveness for these tests. This impacts not only Myriad Genetics but also other companies in the genetic testing space.

Comparison to Industry Standards

• Myriad's 11% revenue growth in Q3 2024 is a strong result compared to some of its peers in the diagnostics industry, although specific comparisons are difficult without detailed competitor data.
• Companies like Exact Sciences and Invitae have also been focusing on expanding their testing portfolios and improving payor coverage, but they face similar challenges with reimbursement.
• The 34% growth in pharmacogenomics revenue is particularly notable, as this area is seeing increased interest and adoption in personalized medicine.
• The impact of UnitedHealthcare's decision on GeneSight coverage is a significant concern, as it highlights the ongoing challenges in securing broad payor acceptance for novel genetic tests. Other companies in the space, such as Genomind, also face similar hurdles.
• Myriad's adjusted EBITDA of $14.1 million is a positive sign of improved profitability, but it is important to compare this to the performance of other diagnostics companies with similar market caps and product portfolios.

Stakeholder Impact

• Shareholders will be impacted by the updated financial guidance and the potential loss of revenue from UnitedHealthcare's policy change.
• Employees may be affected by the company's ongoing cost management activities and strategic initiatives.
• Patients may experience reduced access to GeneSight testing due to UnitedHealthcare's coverage decision.
• Healthcare providers may need to adjust their treatment plans based on changes in test availability and coverage.

Next Steps

• Myriad Genetics will continue to engage with UnitedHealthcare to find a positive resolution for patients regarding GeneSight coverage.
• The company will focus on commercializing new products and expanding payor coverage for its existing tests.
• Myriad will continue to pursue research collaborations and develop new technologies to enhance its product offerings.

Key Dates

Keywords

Myriad Genetics, Genetic Testing, Pharmacogenomics, Prenatal Testing, GeneSight, UnitedHealthcare, Revenue, EBITDA, Financial Results, Healthcare, Precision Medicine, Oncology, Womens Health